Amarhyton is a Class IC antiarrhythmic agent used in the treatment of severe symptomatic life-threatening ventricular arrhythmias and supraventricular arrhythmias.
Amarhyton is used for treatment of:
– AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective;
– Severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy. Also where other treatments have not been tolerated;
– Paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.
Subject to medical prescription.
Concentration and pharmaceutical form: 50 mg; 100 mg; 150 mg prolonged-release capsules, hard